Skip to content
value.today

Indivior PLC: financial analysis

Ratios worked out from 5 fiscal years of Indivior PLC's statements, compared with 102 companies in Pharmaceutical.

Operating margin, 2025
21.2%
Pharmaceutical: 1.8%
Revenue growth, 3 years a year, 2025
11.2%
Pharmaceutical: 2.5%
Free cash flow margin, 2025
-7.5%
Pharmaceutical: 6.0%

Indivior PLC scorecard#

Passes 11 of the 14 checks that could be worked out: strongest in growth (4 of 4), weakest in financial health (3 of 5). Fiscal year 2025; market cap of Aug 1, 2026.

  • Valuationnot known
    • –P/E below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to book below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Price to sales below its peers' medianThe market cap dates from 2026-08-01, more than 60 days ago.
    • –Free cash flow yield above 5%The market cap dates from 2026-08-01, more than 60 days ago.
    • –Earnings yield above the 10-year Treasury yieldThe market cap dates from 2026-08-01, more than 60 days ago.
    • –The price assumes slower growth than the last three years'The market cap dates from 2026-08-01, more than 60 days ago.
  • Growth4 of 4
    • ✓Revenue grew in the newest year4.3%Revenue up 4.3% in fiscal 2025.
    • ✓Revenue up more than 5% a year over three years11.2%11.2% a year over the three years to fiscal 2025.
    • ✓Faster growth over three years than its peers' median11.2%11.2% a year against Pharmaceutical's median of 2.5% (65 companies).
    • ✓Earnings per share grew in the newest year1.64 vs 0.05Diluted EPS 1.64 in fiscal 2025 against 0.05 the year before (report's currency).
    • –Net income higher than five years earlierNet income of five years earlier is not on file.
    • –Revenue rose in at least four of the last five yearsFive years of revenue changes are not on file.
  • Profitability3 of 3
    • ✓Profitable in the newest year$210 MNet income $210 M in fiscal 2025.
    • –Profitable in each of the last five yearsFive years of net income are not on file.
    • ✓Operating margin above its peers' median21.1%21.1% against Pharmaceutical's median of 1.8% (74 companies).
    • –Return on equity above 15%No return on equity (equity missing or negative).
    • –Return on invested capital above 10%No return on invested capital on file.
    • ✓Operating margin wider than three years earlier21.1%21.1% in fiscal 2025 against -9.0% in 2022.
  • Financial health3 of 5
    • ✗Short-term assets cover short-term liabilities0.7×Current ratio 0.71 at the end of fiscal 2025.
    • –Debt below equityDebt or equity is not on file (or equity is negative).
    • ✓Net debt below three years of EBITDA0.3×Net debt 0.3 times EBITDA in fiscal 2025.
    • ✓Operating income covers interest five times6.9×Operating income 6.9 times interest in fiscal 2025.
    • ✗Cash from operations positive in each of the last three years1 of 3Positive in 1 of the three years to fiscal 2025.
    • ✓Altman Z-score outside the distress zone3.45Z-score 3.45 (safe zone) for fiscal 2025.
  • Shareholder returns1 of 2
    • –Pays a dividendDividends are not on file.
    • –Dividend per share raised five years in a rowSix years of dividends per share are not on file.
    • –Dividends under 75% of net incomePays no dividend (or dividends are not on file).
    • ✓Share count up no more than 2% in a year-3.8%Diluted shares down 3.8% in fiscal 2025.
    • –Dividends and buybacks above 3% of the market valueThe market cap dates from 2026-08-01, more than 60 days ago.
    • ✗Free cash flow covers dividends and buybacks-$93 MFree cash flow -$93 M against $11 M paid out in fiscal 2025.

Worked out from the statements as filed (sec), the medians of Pharmaceutical, the 10-year Treasury yield of Nov 13, 2026 and the market cap (too old for the valuation checks, which need one at most 60 days old). A check that cannot be worked out counts neither way. A reading aid, not advice. How the checks work

What the 2025 statements show#

Each line is an observation with its numbers, not a judgement of the company.

Strengths

  • Revenue has grown 3 years in a row.
  • The share count fell 3.8% in the year (buybacks).

Worth a look

  • Free cash flow was negative: -$93 million.
  • Only -13% of net income arrived as cash from operations.
  • Shareholders' equity is negative: -$98 million.
  • Liabilities due within a year exceed current assets (current ratio 0.71).

Piotroski F-score

Nine yes/no tests of whether the company's finances improved in the year. One point each.

4of 9
  • Made a profityes
  • Operations brought in cashno
  • Return on assets roseyes
  • Cash from operations exceeds profitno
  • Long-term debt fell against assetsno
  • Current ratio roseno
  • No new shares issuedyes
  • Gross margin roseno
  • Asset turnover roseyes

Altman Z-score

A 1968 formula that weighs five balance-sheet ratios. It was built on listed manufacturers and says less about other kinds of company.

3.45Safe zone(above 2.99, where the formula's author found few failures)
The five parts of the Altman Z-score
PartRatioWeightPoints
Working capital to assets-0.22× 1.2-0.26
Retained earnings to assets-0.20× 1.4-0.28
Operating income to assets0.22× 3.30.72
Market value to liabilities3.74× 0.62.25
Revenue to assets1.03× 11.03

Profitability#

Indivior PLC: profitability by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Gross margin80.2%80.6%84.1%83.1%—53.3%93%
Operating margin21.2%3.2%-13.9%-9.0%—1.8%85%
Net margin17.0%0.6%-11.5%-4.9%—-1.5%90%
Return on assets16.7%0.5%-7.2%——-1.3%91%

Growth#

Indivior PLC: growth by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Revenue growth4.3%8.7%21.3%——7.3%42%
Revenue growth, 3 years a year11.2%————2.5%75%

Financial strength#

Indivior PLC: financial strength by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Net debt$95 M$-4 M$-79 M——$188 M57%
Net debt to EBITDA0.35×-0.07×———3.19×75%
Interest cover6.89×1.27×-5.63×-4.26×—1.11×84%
Current ratio0.71×0.90×0.98×——1.98×13%
Equity share of assets-8.2%-25.6%-10.5%——47.3%12%

Cash#

Indivior PLC: cash by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Free cash flow$-93 M$7 M$-308 M$-9 M—$8 M2%
Free cash flow margin-7.5%0.6%-28.2%-1.0%—6.0%23%
Cash conversion-12.9%514.3%———136.7%7%
Capital spending share of revenue5.3%2.4%0.7%0.6%—2.6%—

Shareholder returns#

Indivior PLC: shareholder returns by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Buyback yield0.2%————0.6%30%
Shareholder yield0.2%————2.4%4%
Change in share count-3.8%-2.9%-1.4%——1.8%97%

Efficiency#

Indivior PLC: efficiency by fiscal year
Fiscal yearTrend20252024202320222021Median of peersAhead of
Asset turnover0.98×0.77×0.62×——0.55×79%

How each figure is worked out#

Gross margin
Gross profit as a share of revenue.
Operating margin
Operating income as a share of revenue.
Net margin
Net income as a share of revenue.
Return on assets
Net income as a share of total assets (average of the year).
Revenue growth
Revenue against the year before.
Revenue growth, 3 years a year
The yearly rate that takes revenue of three years earlier to this year's.
Net debt
Total debt less cash. Negative means more cash than debt.
Net debt to EBITDA
Debt less cash, divided by operating income plus depreciation and amortization: roughly the years of operating earnings needed to repay it.
Interest cover
Operating income divided by the interest paid on debt.
Current ratio
Assets due within a year divided by liabilities due within a year.
Equity share of assets
Shareholders' equity as a share of total assets.
Free cash flow
Cash from operations less capital spending.
Free cash flow margin
Free cash flow as a share of revenue.
Cash conversion
Cash from operations as a share of net income. Only when the year was profitable.
Capital spending share of revenue
Capital spending as a share of revenue.
Buyback yield
Shares bought back in the fiscal year as a share of today's market value.
Shareholder yield
Dividends plus buybacks as a share of today's market value.
Change in share count
Diluted shares against the year before. Negative: fewer shares.
Asset turnover
Revenue divided by total assets (average of the year).

Source: Indivior PLC's statements: annual reports filed with the SEC. Arithmetic on reported figures, in US dollars; nothing is estimated. A figure is blank when a line it needs is not in the statements on file, and left out when the result cannot be right (a margin from next to no revenue). "Ahead of" is the share of the 102 companies in Pharmaceutical that Indivior PLC is better than on that figure, using each company's newest fiscal year; yields use today's market value. Medians for every industry · Back to Indivior PLC